Saxagliptin: A selective DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

Jay Shubrook, Randall Colucci, Guo Aili, Frank Schwartz

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


The prevalence of type 2 diabetes mellitus is high and growing rapidly. Suboptimal glycemic control provides opportunities for new treatment options to improve the morbidity and mortality of this progressive disease. Saxagliptin, a selective DPP-4 inhibitor, increases endogenous incretin levels and incretin acitivty. In controlled clinical trials saxagliptin reduces both fasting and postprandial glucose and works in monotherapy and in combination with metformin, TZDs and sulfonylureas. Saxagliptin has a very favourable side effect profile and may have other beneficial non-glycemic effects. The authors review the current available evidence for the safety, efficacy and saxagliptin's place in therapy for type 2 diabetes mellitus. As understanding of the incretin hormones (GLP-1, GIP) expand we may see additional important non-glycemic effects that may affect the chronic management of type 2 diabetes mellitus.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalClinical Medicine Insights: Endocrinology and Diabetes
StatePublished - Jan 1 2011
Externally publishedYes


  • DPP-4 inhibitors
  • Incretin hormones
  • Saxagliptin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Saxagliptin: A selective DPP-4 inhibitor for the treatment of type 2 diabetes mellitus'. Together they form a unique fingerprint.

Cite this